Camrelizumab combined with neoadjuvant docetaxel, oxaliplatin, and S1 as induction therapy for locally advanced esophageal squamous cell cancer: a real-world single-center cohort study

• DOI: 10.21037/jtd-2024-2248
• Publication Date: 2025-01-24T02:39:12Z
• Authors: Guanghui Xu; Shushang Liu; Shu Wang; Jiyang Zheng; Yuhao Wang; Haoyuan Wang; Sarbajit Mukherjee; Jianjun Yang
• Keywords: Neoadjuvant Therapy; Squamous cell cancer

Camrelizumab combined with chemotherapy has shown significant clinical benefits in the first-line treatment of advanced esophageal squamous cell cancer (ESCC). Despite promising results from randomized trials, there is a need for real-world evidence to understand broader applicability and long-term outcomes neoadjuvant treatments diverse patient populations ESCC. This study aimed evaluate efficacy safety camrelizumab patients resectable locally ESCC setting. We retrospectively reviewed data 83 advanced, potentially who received docetaxel, oxaliplatin, S1 at Xijing Hospital Digestive Diseases, Fourth Military Medical University March 2020 May 2023. Inclusion criteria were based on stage, histological confirmation, tolerance. Baseline characteristics assessed using standard diagnostic tools. Treatment involved three cycles chemotherapy, evaluated Response Evaluation Criteria Solid Tumors (RECIST) criteria. Tumor downstaging, survival outcomes, assessed. The median age was 61 years (range, 46-75 years), tumors predominantly located middle (n=49, 59.04%) lower (n=23, 27.71%) regions esophagus. Most diagnosed stages III-IV (55.42% 38.55%, respectively), all completed treatment. Additionally, 24 (28.92%) achieved complete response (CR), 40 (48.19%) partial (PR), 9 (10.84%) stable disease (SD). objective rate (ORR) 77.11% (64/83), control (DCR) 87.95% (73/83). Of 14 underwent surgery, R0 resection 100%, 28.57% (4/14) pathological CR (pCR). follow-up time 31.0 months, 3-year overall (OS) 56.9%. incidence grade ≥3 adverse events 6.02% (5/83). No deaths occurred. While our suggest potential plus ESCC, absence group limits generalizability these findings. Further studies are needed validate results.